Methylation profiles of hereditary and sporadic ovarian cancer

Histopathology

Volumn 57, Issue 3, 2010, Pages 363-370

  Bol, Guus M ^a   Suijkerbuijk, Karijn P M ^a   Bart, Joost ^b   Vooijs, Marc ^a   Van Der Wall, Elsken ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

BRCA1 gene; hereditary; methylation; MS MLPA; neoplastic syndromes; ovarian neoplasms

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLUTATHIONE TRANSFERASE P1; PROTEIN MLH1; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; CANCER GRADING; DNA ISOLATION; DNA METHYLATION; ENDOMETRIOID CARCINOMA; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SILENCING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CADHERINS; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 77956645106     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03642.x     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008 58 71 96.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 2000 19 3 10.
3. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005 104 2807 2816.
4. Risch HA, McLaughlin Jr. Cole DEC et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 2006 98 1694 1706.
5. Rubin SC, Blackwood MA, Bandera C et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol. 1998 178 670 677.
6. Antoniou A, Pharoah PDP, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 Studies. Am. J. Hum. Genet. 2003 72 1117 1130.
7. Piek JM, Dorsman JC, Zweemer RP, Verheijen RHM, van Diest PJ. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma. [Letter]. Int. J. Gynecol. Pathol. 2003 22 315.
8. van Beers EH, van Welsem T, Wessels LFA et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005 65 822 827.
9. van der Groep P, Bouter A, Menko F, van der Wall E, van Diest P. High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res. Treat. 2008 111 475 480.
10. van Diest PJ, van der Groep P, van der Wall E. EGFR expression predicts BRCA1 status in patients with breast cancer. Clin. Cancer Res. 2006 12 670.
11. van der Groep P, Bouter A, van der Zanden R et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J. Clin. Pathol. 2006 59 611 617.
12. van der Groep P, Bouter A, van der Zanden R et al. Re: germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2004 96 712 713.
13. Tan DSP, Marchio C, Reis-Filho JS. Hereditary breast cancer: from molecular pathology to tailored therapies. J. Clin. Pathol. 2008 61 1073 1082.
14. Zweemer RP, Verheijen RH, Gille JJ, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am. J. Obstet. Gynecol. 1998 178 85 90.
15. Zweemer RP, Verheijen RH, Menko FH et al. Differences between hereditary and sporadic ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 1999 82 151 153.
16. Zweemer RP, Ryan A, Snijders AM et al. Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab. Invest. 2001 81 1363 1370.
17. Jongsma AP, Piek JM, Zweemer RP et al. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol. Pathol. 2002 55 305 309.
18. Piek JM, Torrenga B, Hermsen B et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer 2003 2 73 78.
19. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 2002 94 990 1000.
20. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003 349 2042 2054.
21. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000 16 168 174.
22. Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000 24 132 138.
23. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007 16 R50 R59.
24. Suijkerbuijk KPM, Fackler MJ, Sukumar S et al. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann. Oncol. 2008 19 1870 1874.
25. van Diest PJ, Savulescu J. For and against: no consent should be needed for using leftover body material for scientific purposes. BMJ 2002 325 648 651.
26. Announcements. FIGO stages - 1988 revision. Gynecol. Oncol. 1989 35 125 127.
27. Nygren AOH, Ameziane N, Duarte HMB et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic. Acids Res. 2005 33 e128.
28. Jeuken JW, Cornelissen SJ, Vriezen M et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab. Invest. 2007 87 1055 1065.
29. Gylling A, Abdel-Rahman WM, Juhola M et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 2007 56 926 933.
30. Strathdee G, Appleton K, Illand M et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001 158 1121 1127.
31. Rathi A, Virmani AK, Schorge JO et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 2002 8 3324 3331.
32. Makarla PB, Saboorian MH, Ashfaq R et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res. 2005 11 5365 5369.
33. Wiley A, Katsaros D, Chen H et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006 107 299 308.
34. Tam K, Liu V, Liu S et al. Methylation profile in benign, borderline and malignant ovarian tumors. J. Cancer Res. Clin. Oncol. 2007 133 331.
35. Wu Q, Lothe R, Ahlquist T et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol. Cancer 2007 6 45.
36. Baldwin RL, Nemeth E, Tran H et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000 60 5329 5333.
37. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 2003 9 568 574.
38. Esteller M, Fraga MF, Guo M et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 2001 10 3001 3007.
39. Swisher E, Gonzalez R, Taniguchi T et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol. Cancer 2009 8 48.
40. Kwabi-Addo B, Chung W, Shen L et al. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 2007 13 3796 3802.
41. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa J-PJ. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998 58 5489 5494.
42. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000 283 2260 2265.
43. Lakhani SR, Manek S, Penault-Llorca F et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 2004 10 2473 2481.
44. Bell DA. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 2005 18 S19 S32.
45. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004 164 1511 1518.